Table of Contents

company-logo

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Ocular Therapeutix Dividend Announcement

• Ocular Therapeutix does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Ocular Therapeutix dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Ocular Therapeutix Dividend History

Ocular Therapeutix Dividend Yield

Ocular Therapeutix current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Ocular Therapeutix stock? Use our calculator to estimate your expected dividend yield:

Ocular Therapeutix Financial Ratios

P/E ratio-8.71
PEG ratio0.18
P/B ratio4.31
ROE-56.75%
Payout ratio0.00%
Current ratio13.01
Quick ratio12.94
Cash Ratio11.75

Ocular Therapeutix Dividend FAQ

Does Ocular Therapeutix stock pay dividends?
Ocular Therapeutix does not currently pay dividends to its shareholders.
Has Ocular Therapeutix ever paid a dividend?
No, Ocular Therapeutix has no a history of paying dividends to its shareholders. Ocular Therapeutix is not known for its dividend payments.
Why doesn't Ocular Therapeutix pay dividends?
There are several potential reasons why Ocular Therapeutix would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Ocular Therapeutix ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Ocular Therapeutix has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Ocular Therapeutix a dividend aristocrat?
Ocular Therapeutix is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Ocular Therapeutix a dividend king?
Ocular Therapeutix is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Ocular Therapeutix a dividend stock?
No, Ocular Therapeutix is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Ocular Therapeutix stocks?
To buy Ocular Therapeutix you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Ocular Therapeutix stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.